Share on LinkedInShare on LinkedIn

ARTICLE · 25 MAY 2016

GSK's Philanthropy

Multinational Pharmaceutical companies are often accused of exorbitant pricing, using surreptitious ways to extend the patent protection for their drugs (read – ever greening) etc.

IndiaIntellectual Property

Multinational Pharmaceutical companies are often accused of exorbitant pricing, using surreptitious ways to extend the patent protection for their drugs (read – ever greening) etc. In an attempt to prove such accusations incorrect GSK, a leading pharmaceutical Company has recently announced that it will stop filing for patents in less developing countries thereby allowing the generic manufacturers for such countries to make cheap copies of their drugs and increase its access among the public.

As for its plan for the middle income countries, GSK aims at filing patents in those countries but will charge a small sales royalty thereby allowing for sale of original drugs at a lesser price. This development is a cause for celebration for the countries falling in the abovementioned categories but GSK has expressly specified that it will continue to seek full patent protection in countries like India, China and Brazil. It has further announced that it will allow its

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from